DC
LEGN icon

Decheng Capital’s Legend Biotech LEGN Stock Holding History

Decheng Capital’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,000
Closed -$710K – 25
2025
Q2 		$710K Sell
20,000
-80,000
-80% -$2.59M 0.18% 21
2025
Q1 		$3.39M Sell
100,000
-53,558
-35% -$1.92M 0.95% 16
2024
Q4 		$5M Buy
153,558
+45,000
+41% +$1.86M 1.07% 18
2024
Q3 		$5.29M Buy
108,558
+10,000
+10% +$533K 1.25% 13
2024
Q2 		$4.37M Buy
98,558
+12,195
+14% +$563K 1.34% 15
2024
Q1 		$4.84M Buy
+86,363
New +$5.21M 0.65% 15

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Decheng Capital's LEGN Position: Q3 2025 in Review

Decheng Capital sold out of Legend Biotech (LEGN) in Q3 2025, closing a stake of 20,000 shares — an estimated $710K sold.

Decheng Capital first reported a position in LEGN in Q1 2024 and held it in 6 quarters. The position peaked at $5.29M in Q3 2024. 200 funds tracked by Wall St. Rank hold LEGN as of Q3 2025.

  • Decheng Capital reported no remaining Legend Biotech position as of Q3 2025 after selling out during the quarter.
  • Decheng Capital sold 20,000 Legend Biotech shares in Q3 2025, an estimated $710K.
  • Decheng Capital first reported a position in Legend Biotech in Q1 2024 and held it in 6 quarters.
  • Decheng Capital's Legend Biotech position peaked at $5.29M in Q3 2024.
  • 200 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2025.

Based on Decheng Capital's 13F filing for Q3 2025, filed 14 Nov 2025.